NASDAQ:CDMO - Avid Bioservices Stock Price, Forecast & News

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Avid Bioservices shares reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

Avid Bioservices Inc (NASDAQ:CDMO) issued its quarterly earnings results on Monday, December, 9th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.01. The biopharmaceutical company had revenue of $18.31 million for the quarter, compared to analysts' expectations of $14.34 million. Avid Bioservices had a negative net margin of 6.83% and a negative return on equity of 8.78%. The company's revenue was up 79.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.05) earnings per share. View Avid Bioservices' Earnings History.

Avid Bioservices is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Avid Bioservices.

5 Wall Street analysts have issued 12-month target prices for Avid Bioservices' shares. Their forecasts range from $7.50 to $11.00. On average, they anticipate Avid Bioservices' share price to reach $9.90 in the next year. This suggests a possible upside of 37.9% from the stock's current price. View Analyst Price Targets for Avid Bioservices.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avid Bioservices.

Press coverage about CDMO stock has been trending very negative recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Avid Bioservices earned a media sentiment score of -3.6 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Avid Bioservices.

Some companies that are related to Avid Bioservices include Alder Biopharmaceuticals (ALDR), TG Therapeutics (TGTX), Corcept Therapeutics (CORT), Constellation Pharmaceuticals (CNST), IGM Biosciences (IGMS), Innoviva (INVA), Nabriva Therapeutics (NBRV), ZEALAND PHARMA/S (ZEAL), Theravance Biopharma (TBPH), Madrigal Pharmaceuticals (MDGL), Dicerna Pharmaceuticals (DRNA), BELLUS Health (BLUSF), Endo International (ENDP), Amneal Pharmaceuticals (AMRX) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Biopharma (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), AcelRx Pharmaceuticals (ACRX), TransEnterix (TRXC), Advanced Micro Devices (AMD), Novavax (NVAX), XOMA (XOMA), SLS International (SLS) and AVEO Pharmaceuticals (AVEO).

Avid Bioservices' stock is owned by many different of institutional and retail investors. Top institutional investors include AltraVue Capital LLC (3.93%), State Street Corp (1.88%), Sargent Investment Group LLC (1.71%), Sargent Investment Group LLC (1.59%), Geode Capital Management LLC (1.24%) and Essex Investment Management Co. LLC (0.80%). Company insiders that own Avid Bioservices stock include Joel Mccomb, Joseph Carleone and Richard B Hancock. View Institutional Ownership Trends for Avid Bioservices.

CDMO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Geode Capital Management LLC, Schonfeld Strategic Advisors LLC, Crestwood Advisors Group LLC, Jefferies Group LLC, AltraVue Capital LLC, New York State Common Retirement Fund and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for Avid Bioservices.

CDMO stock was acquired by a variety of institutional investors in the last quarter, including Sargent Investment Group LLC, EAM Global Investors LLC, Sargent Investment Group LLC, Renaissance Technologies LLC, Oxford Asset Management LLP, Parkman Healthcare Partners LLC, Bank of Montreal Can and EAM Investors LLC. Company insiders that have bought Avid Bioservices stock in the last two years include Joseph Carleone and Richard B Hancock. View Insider Buying and Selling for Avid Bioservices.

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CDMO stock can currently be purchased for approximately $7.18.

Avid Bioservices has a market capitalization of $404.52 million and generates $53.60 million in revenue each year. The biopharmaceutical company earns $-4,220,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Avid Bioservices employs 185 workers across the globe.View Additional Information About Avid Bioservices.

The official website for Avid Bioservices is http://www.avidbio.com/.

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]